Vivos Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M |
| Cost of Revenue | $6.9M | $6.0M | $5.5M | $200.0K | $400.0K | $100.0K | — |
| Gross Profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M | $8.7M |
| Gross Margin | 60.4% | 60.0% | 59.9% | 62.5% | 74.6% | 79.7% | 76.0% |
| Operating Expenses | |||||||
| Research & Development | $100.0K | $100.0K | $100.0K | $200.0K | $200.0K | — | — |
| SG&A Expense | $27.7M | $17.9M | $22.5M | $29.0M | $25.8M | $16.1M | $16.2M |
| Operating Income | $-19.9M | $-11.2M | $-17.3M | $-25.0M | $-20.4M | $-12.0M | $-10.6M |
| Operating Margin | -114.1% | -74.3% | -125.3% | -156.2% | -120.7% | -92.1% | -92.8% |
| Interest Expense | $1.4M | — | — | — | $14.0K | $96.0K | $137.9K |
| Pretax Income | $-21.2M | $-11.1M | $-13.6M | $-23.8M | $-20.3M | $-12.1M | $-10.8M |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | $-21.2M | $-11.1M | $-13.6M | $-23.8M | $-20.3M | $-12.1M | $-10.8M |
| Net Margin | -121.4% | -74.1% | -98.4% | -148.8% | -120.2% | -92.3% | -94.4% |
| EPS (Basic) | $-2.07 | $-1.11 | $-1.39 | $-3.24 | $-0.12 | $-0.18 | $-0.12 |
| EPS (Diluted) | $-2.07 | $-1.11 | $-1.39 | $-3.24 | $-0.12 | $-0.18 | $-0.12 |
| Shares Outstanding (Basic) | 10.3M | 10.0M | 9.8M | 184.10B | 169.87B | 145.7M | 99.6M |
| Shares Outstanding (Diluted) | 10.3M | 10.0M | 9.8M | 7.4M | 169.87B | 145.7M | 99.6M |
| Dividends Per Share | — | — | — | — | — | — | — |